{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T22:03:48Z","timestamp":1785708228956,"version":"3.56.0"},"reference-count":93,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004489","name":"MITACS Canada (UBC) student fellowship","doi-asserted-by":"publisher","award":["22R07416"],"award-info":[{"award-number":["22R07416"]}],"id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004489","name":"MITACS Canada (UBC) student fellowship","doi-asserted-by":"publisher","award":["IT01787"],"award-info":[{"award-number":["IT01787"]}],"id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004489","name":"MITACS Canada (UBC) student fellowship","doi-asserted-by":"publisher","award":["11R17370"],"award-info":[{"award-number":["11R17370"]}],"id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004489","name":"MITACS Canada (UBC) student fellowship","doi-asserted-by":"publisher","award":["20R67183"],"award-info":[{"award-number":["20R67183"]}],"id":[{"id":"10.13039\/501100004489","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MITACS Elevate fellowship","award":["22R07416"],"award-info":[{"award-number":["22R07416"]}]},{"name":"MITACS Elevate fellowship","award":["IT01787"],"award-info":[{"award-number":["IT01787"]}]},{"name":"MITACS Elevate fellowship","award":["11R17370"],"award-info":[{"award-number":["11R17370"]}]},{"name":"MITACS Elevate fellowship","award":["20R67183"],"award-info":[{"award-number":["20R67183"]}]},{"name":"Kisameet Glacial Clay Inc.","award":["22R07416"],"award-info":[{"award-number":["22R07416"]}]},{"name":"Kisameet Glacial Clay Inc.","award":["IT01787"],"award-info":[{"award-number":["IT01787"]}]},{"name":"Kisameet Glacial Clay Inc.","award":["11R17370"],"award-info":[{"award-number":["11R17370"]}]},{"name":"Kisameet Glacial Clay Inc.","award":["20R67183"],"award-info":[{"award-number":["20R67183"]}]},{"name":"Tally Fund","award":["22R07416"],"award-info":[{"award-number":["22R07416"]}]},{"name":"Tally Fund","award":["IT01787"],"award-info":[{"award-number":["IT01787"]}]},{"name":"Tally Fund","award":["11R17370"],"award-info":[{"award-number":["11R17370"]}]},{"name":"Tally Fund","award":["20R67183"],"award-info":[{"award-number":["20R67183"]}]},{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","award":["22R07416"],"award-info":[{"award-number":["22R07416"]}],"id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","award":["IT01787"],"award-info":[{"award-number":["IT01787"]}],"id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","award":["11R17370"],"award-info":[{"award-number":["11R17370"]}],"id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000082","name":"Cystic Fibrosis Canada","doi-asserted-by":"publisher","award":["20R67183"],"award-info":[{"award-number":["20R67183"]}],"id":[{"id":"10.13039\/501100000082","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>There is an impending crisis in healthcare brought about by a new era of untreatable infections caused by bacteria resistant to all available antibiotics. Thus, there is an urgent need to identify novel antimicrobial agents to counter the continuing threat posed by formerly treatable infections. We previously reported that a natural mineral clay known as Kisameet clay (KC) is a potent inhibitor of the organisms responsible for acute infections. Chronic bacterial infections present another major challenge to treatment by antimicrobials, due to their prolonged nature, which results in repeated exposure to antibiotics and a constant selection for antimicrobial resistance. A prime example is bacteria belonging to the Burkholderia cepacia complex (Bcc), which particularly causes some of the most serious chronic lung infections in patients with cystic fibrosis (CF) associated with unpredictable clinical outcomes, poor prognosis, and high mortality rates. Eradication of these organisms from CF patients with limited effective antimicrobial options is a major challenge. Novel therapeutic approaches are urgently required. Here, we report the in vitro antibacterial activity of KC aqueous suspensions (1\u201310% w\/v) and its aqueous extract (L100) against a collection of extensively and multi-drug resistant clinical isolates of Bcc, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia isolated from patients with CF. These findings present a potential novel therapy for further investigation in the clinic.<\/jats:p>","DOI":"10.3390\/microorganisms11010150","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T02:31:30Z","timestamp":1673231490000},"page":"150","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Antibacterial Activity of a Natural Clay Mineral against Burkholderia cepacia Complex and Other Bacterial Pathogens Isolated from People with Cystic Fibrosis"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-9059","authenticated-orcid":false,"given":"Shekooh","family":"Behroozian","sequence":"first","affiliation":[{"name":"Department of Chemical and Biological Engineering, University of British Columbia, 2360 E Mall, Vancouver, BC V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E. A.","family":"Zlosnik","sequence":"additional","affiliation":[{"name":"Centre for Understanding and Preventing Infection in Children, Division of Infectious Diseases, Department of Pediatrics, BC Children\u2019s Hospital Research Institute, University of British Columbia, Vancouver, BC V5Z 4H4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Civil Engineering, University of British Columbia, 6250 Applied Science Ln, Vancouver, BC V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta Y.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Civil Engineering, University of British Columbia, 6250 Applied Science Ln, Vancouver, BC V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian E.","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4161\/viru.23987","article-title":"Persistent bacterial infections, antibiotic tolerance, and the oxidative stress response","volume":"4","author":"Grant","year":"2013","journal-title":"Virulence"},{"key":"ref_2","first-page":"Doc05","article-title":"Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria?","volume":"12","author":"Exner","year":"2017","journal-title":"GMS Hyg. Infect. Control"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.3928\/19382359-20190327-01","article-title":"Review of Cystic Fibrosis","volume":"48","author":"Goetz","year":"2019","journal-title":"Pediatr. Ann."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","article-title":"Cystic fibrosis","volume":"1","author":"Ratjen","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CMR.15.2.194-222.2002","article-title":"Lung infections associated with cystic fibrosis","volume":"15","author":"Lyczak","year":"2002","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease","volume":"56","author":"Andersen","year":"1938","journal-title":"Am. J. Dis. Child."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1073\/pnas.87.21.8447","article-title":"Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene","volume":"87","author":"Kerem","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2015.10.002","article-title":"Epidemiology of Cystic Fibrosis","volume":"37","author":"Spoonhower","year":"2016","journal-title":"Clin. Chest Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Scotet, V., L\u2019Hostis, C., and F\u00e9rec, C. (2020). The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes, 11.","DOI":"10.3390\/genes11060589"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: A disease with a new face","volume":"109","year":"2020","journal-title":"Acta Paediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ame2.12180","article-title":"A review of cystic fibrosis: Basic and clinical aspects","volume":"4","author":"Chen","year":"2021","journal-title":"Anim. Model. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: From molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/17476348.2019.1552832","article-title":"Acute and chronic non-pulmonary complications in adults with cystic fibrosis","volume":"13","author":"Regard","year":"2019","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1055\/s-0039-1697639","article-title":"Pulmonary Complications of Cystic Fibrosis","volume":"40","author":"Garcia","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Filkins, L.M., and O\u2019Toole, G.A. (2015). Cystic Fibrosis Lung Infections: Polymicrobial, Complex, and Hard to Treat. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005258"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S1526-0550(02)00003-3","article-title":"Pseudomonas aeruginosa in cystic fibrosis: Pathogenesis and persistence","volume":"3","author":"Davies","year":"2002","journal-title":"Paediatr. Resp. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1128\/CMR.00068-09","article-title":"The changing microbial epidemiology in cystic fibrosis","volume":"23","author":"Lipuma","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00253-010-2528-0","article-title":"Pathogenicity, virulence factors, and strategies to fight against Burkholderia cepacia complex pathogens and related species","volume":"87","author":"Sousa","year":"2010","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jinf.2018.07.006","article-title":"Burkholderia cepacia complex infections: More complex than the bacterium name suggest","volume":"77","author":"Sfeir","year":"2018","journal-title":"J. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12941-019-0306-0","article-title":"Accurate identification and epidemiological characterization of Burkholderia cepacia complex: An update","volume":"18","author":"Ragupathi","year":"2019","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13062-020-0258-5","article-title":"Genome-based classification of Burkholderia cepacia complex provides new insight into its taxonomic status","volume":"15","author":"Jin","year":"2020","journal-title":"Biol. Direct"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1203\/00006450-197704000-00792","article-title":"Pseudomonas cepacia in the respiratory flora of patients with cystic fibrosis (CF)","volume":"11","author":"Lipstein","year":"1977","journal-title":"Pediatr. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1099\/00207713-47-4-1188","article-title":"Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov","volume":"47","author":"Vandamme","year":"1997","journal-title":"Int. J. Syst. Evol. Bacteriol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0022-3476(85)80511-4","article-title":"Pseudomonas cepacia colonization in patients with cystic fibrosis: Risk factors and clinical outcome","volume":"107","author":"Tablan","year":"1985","journal-title":"J. Pediatr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.12688\/f1000research.8221.1","article-title":"Members of the genus Burkholderia: Good and bad guy","volume":"5","author":"Eberl","year":"2016","journal-title":"F1000Research"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/01.mcp.0000181475.85187.ed","article-title":"Update on the Burkholderia cepacia complex","volume":"11","author":"Lipuma","year":"2005","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrmicro1085","article-title":"The multifarious, multireplicon Burkholderia cepacia complex","volume":"3","author":"Mahenthiralingam","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1526-0542(02)00185-9","article-title":"Advances in Burkholderia cepacia complex","volume":"3","author":"Speert","year":"2002","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Leit\u00e3o, J.H., Feliciano, J.R., Sousa, S.A., and Guerreiro, T.P.A.I. (2017). Burkholderia cepacia Complex Infections Among Cystic Fibrosis Patients: Perspectives and Challenges. Progress in Understanding Cystic Fibrosis, IntechOpen.","DOI":"10.5772\/67712"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0272-5231(05)70094-0","article-title":"Burkholderia cepacia. Management issues and new insights","volume":"19","author":"LiPuma","year":"1998","journal-title":"Clin. Chest Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3389\/fmicb.2017.01592","article-title":"Burkholderia cenocepacia Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches","volume":"8","author":"Scoffone","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: A global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"621342","DOI":"10.1155\/2014\/621342","article-title":"Practical guidelines: Lung transplantation in patients with cystic fibrosis","volume":"2014","author":"Hirche","year":"2014","journal-title":"Pulm. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(01)06808-8","article-title":"Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis","volume":"358","author":"McDowell","year":"2001","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/j.1365-2672.2007.03706.x","article-title":"Burkholderia cepacia complex bacteria: Opportunistic pathogens with important natural biology","volume":"104","author":"Mahenthiralingam","year":"2008","journal-title":"J. Appl. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s10096-008-0552-0","article-title":"Variation of the antimicrobial susceptibility profiles of Burkholderia cepacia complex clonal isolates obtained from chronically infected cystic fibrosis patients: A five-year survey in the major Portuguese treatment center","volume":"27","author":"Sousa","year":"2008","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.drup.2016.07.003","article-title":"Antibiotic resistance in Burkholderia species","volume":"28","author":"Rhodes","year":"2016","journal-title":"Drug Resist. Update"},{"key":"ref_39","first-page":"CD009529","article-title":"Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation","volume":"4","author":"Lord","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_40","first-page":"CD009876","article-title":"Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis","volume":"4","author":"Regan","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1513\/AnnalsATS.201408-395OC","article-title":"Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years\u2019 experience","volume":"12","author":"Zlosnik","year":"2015","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1128\/JB.184.20.5678-5685.2002","article-title":"Biofilm formation and acyl homoserine lactone production in the Burkholderia cepacia complex","volume":"184","author":"Conway","year":"2002","journal-title":"J. Bacteriol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4187\/aarc0492","article-title":"Bugs, biofilms, and resistance in cystic fibrosis","volume":"54","author":"Davies","year":"2009","journal-title":"Respir. Care"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.addr.2014.11.017","article-title":"Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients","volume":"85","author":"Ciofu","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jcf.2015.02.005","article-title":"Cystic fibrosis microbiology: Advances in antimicrobial therapy","volume":"14","author":"Waters","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CMR.00030-10","article-title":"Challenges of antibacterial discovery","volume":"24","author":"Silver","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/mmi.14481","article-title":"An ancient solution to a modern problem","volume":"113","author":"Davies","year":"2020","journal-title":"Mol. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0169-1317(01)00085-0","article-title":"Clay minerals and their beneficial effect upon human health. A review","volume":"21","author":"Carretero","year":"2002","journal-title":"Appl. Clay Sci."},{"key":"ref_49","first-page":"3","article-title":"Killer clays! Natural antibacterial clay minerals","volume":"139","author":"Williams","year":"2004","journal-title":"Miner. Soc. Bull."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clay.2006.08.006","article-title":"Minerals and clay minerals in medical geology","volume":"36","author":"Gomes","year":"2007","journal-title":"Appl. Clay Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1572-4352(05)01024-X","article-title":"Clays and human health","volume":"Volume 1","author":"Bergaya","year":"2006","journal-title":"Handbook of Clay Science, Developments in Clay Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s10653-016-9903-4","article-title":"Healing and edible clays: A review of basic concepts, benefits and risks","volume":"40","author":"Gomes","year":"2018","journal-title":"Environ. Geochem. Health"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Velde, B. (1995). Geology of clays. Origin and Mineralogy of Clays, Clays and the Environment, Springer.","DOI":"10.1007\/978-3-662-12648-6"},{"key":"ref_54","first-page":"21","article-title":"Structure and Mineralogy of Clay Minerals","volume":"Volume 1","author":"Bergaya","year":"2006","journal-title":"Handbook of Clay Science, Developments in Clay Science"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1007\/s11661-008-9603-5","article-title":"Clays, nanoclays, and montmorillonite minerals","volume":"39","author":"Uddin","year":"2008","journal-title":"Met. Mater. Trans. A"},{"key":"ref_56","unstructured":"World Health Organization (2002). Draft Report of the 5th WHO Advisory Group Meeting on Buruli Ulcer, Study group report on Buruli Ulcer treatment with clay."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1346\/CCMN.2008.0560405","article-title":"Chemical and mineralogical characteristics of French green clays used for healing","volume":"56","author":"Williams","year":"2008","journal-title":"Clays Clay Miner."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jac\/dkm468","article-title":"Broad-spectrum in vitro antibacterial activities of clay minerals against antibiotic-susceptible and antibiotic-resistant bacterial pathogens","volume":"61","author":"Haydel","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1021\/es1040688","article-title":"What makes a natural clay antibacterial?","volume":"45","author":"Williams","year":"2011","journal-title":"Environ. Sci. Technol."},{"key":"ref_60","first-page":"547","article-title":"Mineralogy of southern Africa medicinal and cosmetic clays and their effects on the growth of selected test microorganisms","volume":"17","author":"Mpuchane","year":"2008","journal-title":"Fresenius Environ. Bull."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"19043","DOI":"10.1038\/srep19043","article-title":"Unearthing the antibacterial mechanism of medicinal clay: A geochemical approach to combating antibiotic resistance","volume":"6","author":"Morrison","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_62","unstructured":"Hauser, E.A. (1952). Kisameet Bay Clay Deposit. Problems of Clay and Laterite Genesis Symposium at Annual Meeting of the American Institute of Mining and Metallurgical Engineers, St. Louis, MO, USA, 19\u201322 February 1951, The American Institute of Mining and Metallurgical Engineers."},{"key":"ref_63","first-page":"230","article-title":"Curative properties of rare earths found in B.C. peloid deposits","volume":"22","author":"Ure","year":"1946","journal-title":"Bull. Vanc. Med. Assoc."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e00590-17","DOI":"10.1128\/mBio.00590-17","article-title":"Kisameet Glacial Clay: An Unexpected Source of Bacterial Diversity","volume":"8","author":"Svensson","year":"2017","journal-title":"mBio"},{"key":"ref_65","unstructured":"Behroozian, S. (2019). Antimicrobial Properties of Kisameet Clay, A Natural Clay Mineral from British Columbia, Canada. [Ph.D. Thesis, University of British Columbia]. Available online: http:\/\/open.library.ubc.ca\/collections\/ubctheses\/24\/items\/1.0380811."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e02350-20","DOI":"10.1128\/mBio.02350-20","article-title":"Broad-Spectrum Antimicrobial and Antibiofilm Activity of a Natural Clay Mineral from British Columbia, Canada","volume":"11","author":"Behroozian","year":"2020","journal-title":"mBio"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e01842-15","DOI":"10.1128\/mBio.01842-15","article-title":"Kisameet clay exhibits potent antibacterial activity against the ESKAPE pathogens","volume":"7","author":"Behroozian","year":"2016","journal-title":"mBio"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1164\/rccm.2203011","article-title":"Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada","volume":"166","author":"Speert","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3201\/eid0802.010163","article-title":"Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada","volume":"8","author":"Speert","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/ajcp\/45.4_ts.493","article-title":"Antibiotic susceptibility testing by a standardized single disk method","volume":"45","author":"Bauer","year":"1966","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_71","unstructured":"Hudzicki, J. (2016, June 19). Kirby-Bauer Disk Diffusion Susceptibility Test Protocol. American Society for Microbiology. Available online: https:\/\/asm.org\/Protocols\/Kirby-Bauer-Disk-Diffusion-Susceptibility-Test-Pro."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Miller, R.R., Hird, T.J., Tang, P., and Zlosnik, J.E. (2015). Whole-Genome Sequencing of Three Clonal Clinical Isolates of B. cenocepacia from a Patient with Cystic Fibrosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143472"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/655663","article-title":"The role of mucoidy in virulence of bacteria from the Burkholderia cepacia complex: A systematic proteomic and transcriptomic analysis","volume":"202","author":"Zlosnik","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e00029-16","DOI":"10.1128\/mSystems.00029-16","article-title":"Long-Term Evolution of Burkholderia multivorans during a Chronic Cystic Fibrosis Infection Reveals Shifting Forces of Selection","volume":"1","author":"Silva","year":"2016","journal-title":"mSystems"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1128\/AAC.02068-15","article-title":"Activity of Tobramycin against Cystic Fibrosis Isolates of Burkholderia cepacia Complex Grown as Biofilms","volume":"60","author":"Kennedy","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Bryskier, A. (2005). Aminocyclitol aminoglycosides. Antimicrobial Agents, ASM Press.","DOI":"10.1128\/9781555815929"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drup.2010.08.003","article-title":"Aminoglycoside modifying enzymes","volume":"13","author":"Ramirez","year":"2010","journal-title":"Drug Resist. Update"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e00590-18","DOI":"10.1128\/AAC.00590-18","article-title":"In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam","volume":"62","author":"Herpol","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e00181-19","DOI":"10.1128\/JCM.00181-19","article-title":"\u201cSwitching Partners\u201d: Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates","volume":"57","author":"Zeiser","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13756-017-0279-8","article-title":"Novel antibiotic combinations proposed for treatment of Burkholderia cepacia complex infections","volume":"6","author":"Naguib","year":"2017","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Vasireddy, L., Bingle, L., and Davies, M.S. (2018). Antimicrobial activity of essential oils against multidrug-resistant clinical isolates of the Burkholderia cepacia complex. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0201835"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"573518","DOI":"10.1155\/2014\/573518","article-title":"Exploring the Anti-Burkholderia cepacia Complex Activity of Essential Oils: A Preliminary Analysis","volume":"2014","author":"Maida","year":"2014","journal-title":"Evid.-Based Complement. Altern. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jcf.2017.02.008","article-title":"Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection","volume":"16","author":"Waters","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1513\/AnnalsATS.201812-863OT","article-title":"Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities","volume":"16","author":"Nichols","year":"2019","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1128\/AAC.02388-13","article-title":"Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections","volume":"58","author":"Semler","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Pradenas, G.A., Ross, B.N., and Torres, A.G. (2016). Burkholderia cepacia Complex Vaccines: Where Do We Go from here?. Vaccines, 4.","DOI":"10.3390\/vaccines4020010"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.medmal.2015.11.013","article-title":"Vaccine strategies against bacterial pathogens in cystic fibrosis patients","volume":"46","author":"Gaillard","year":"2016","journal-title":"Med. Mal. Infect."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1469-0691.2010.03237.x","article-title":"Burkholderia cenocepacia in cystic fibrosis: Epidemiology and molecular mechanisms of virulence","volume":"16","author":"Drevinek","year":"2010","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"15008","DOI":"10.1038\/nmicrobiol.2015.8","article-title":"Predicted global distribution of Burkholderia pseudomallei and burden of melioidosis","volume":"1","author":"Limmathurotsakul","year":"2016","journal-title":"Nat. Microbiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e00006-19","DOI":"10.1128\/CMR.00006-19","article-title":"Human Melioidosis","volume":"33","author":"Gassiep","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Nunvar, J., Capek, V., Fiser, K., Fila, L., and Drevinek, P. (2017). What matters in chronic Burkholderia cenocepacia infection in cystic fibrosis: Insights from comparative genomics. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006762"},{"key":"ref_93","unstructured":"Bish, D.L. (2015, June 26). Studies of Clays and Clay Minerals Using X-ray Powder Diffraction and the Rietveld Method. United States, Available online: http:\/\/www.osti.gov\/servlets\/purl\/10192067."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/1\/150\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:01:32Z","timestamp":1760119292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/1\/150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["microorganisms11010150"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms11010150","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]}}}